摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-bromo-1-phenylquinoxalin-2(1H)-one | 1201845-33-1

中文名称
——
中文别名
——
英文名称
7-bromo-1-phenylquinoxalin-2(1H)-one
英文别名
7-bromo-1-phenylquinoxalin-2-one
7-bromo-1-phenylquinoxalin-2(1H)-one化学式
CAS
1201845-33-1
化学式
C14H9BrN2O
mdl
——
分子量
301.142
InChiKey
BOELYTMMBBZTPY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    32.7
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • INHIBITORS OF PI3 KINASE
    申请人:Bo Yunxin Y.
    公开号:US20110092504A1
    公开(公告)日:2011-04-21
    The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X 1 , X 2 , R 1 and Z are as defined herein.
    本发明涉及式(I)的化合物,或其药学上可接受的盐;使用该化合物治疗疾病或病症的方法,例如癌症;以及含有该化合物的制药组合物,其中Q、X1、X2、R1和Z的定义如本文所述。
  • Inhibitors of PI3 kinase
    申请人:Bo Yunxin Y.
    公开号:US08415376B2
    公开(公告)日:2013-04-09
    The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein Q, X1, X2, R1 and Z are as defined herein.
    本发明涉及公式(I)的化合物或其药学上可接受的盐;使用这些化合物治疗癌症等疾病或病况的方法;以及含有这些化合物的制药组合物,其中Q、X1、X2、R1和Z的定义如本文所述。
  • Concise SAR Exploration Based on the “Head-to-Tail” Approach: Discovery of PI4KIIIα Inhibitors Bearing Diverse Scaffolds
    作者:Satoru Noji、Noriyoshi Seki、Takaki Maeba、Takayuki Sakai、Eiichi Watanabe、Katsuya Maeda、Kyoko Fukushima、Toru Noguchi、Kazuya Ogawa、Yukiyo Toyonaga、Tamotsu Negoro、Hisashi Kawasaki、Makoto Shiozaki
    DOI:10.1021/acsmedchemlett.6b00232
    日期:2016.10.13
    In typical kinase inhibitor programs, a hinge binder showing best potency with preferential specificity is initially selected, followed by fine-tuning of the accompanying substituents on its core module. A shortcoming of this approach is that the exclusive focus on a single chemotype can endanger all the analogues in the series if a critical shortcoming is revealed. Thus, an early evaluation of structure activity relationships (SARs) can mitigate unforeseen outcomes within a series of multiple compounds, although there have been very few examples to follow such a policy. PI4KIII alpha is one of four mammalian phosphatidylinositol-4 kinases and has recently drawn significant attention as an emerging target for hepatitis C virus (HCV) treatment. In this letter, a novel "head-to-tail" approach to discover a diverse set of PI4KIII alpha inhibitors is reported. We believe this method will generate distinct core scaffolds, a rational strategy to circumvent potential risks in general kinase programs.
  • US8415376B2
    申请人:——
    公开号:US8415376B2
    公开(公告)日:2013-04-09
  • [EN] INHIBITORS OF PI3 KINASE<br/>[FR] INHIBITEURS DE LA PI3 KINASE
    申请人:AMGEN INC
    公开号:WO2009155121A3
    公开(公告)日:2010-02-18
查看更多